EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose

Vikas Garg, Bharath B Gangadharaiah, Sameer Rastogi, Ashish Upadhyay, Adarsh Barwad, Ekta Dhamija, Shivanand Gamangatti

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.03.017 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Vikas Garg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, BRAIRCH, AIIMS, Delhi, India. Electronic address: vg18007@gmail.com. Hauptthemen laut MEDLINE: Antineoplastic Agents, Desmoid Tumors, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDesmoid TumorsDrug-Related Side Effects and Adverse ReactionsFemaleHumansAdolescentYoung AdultAdultMiddle AgedAgedAged, 80 and overMaleSorafenibProtein Kinase InhibitorsNiacinamidePhenylurea CompoundsAlopecia

Stichwörter der Autor:innen

DTFDesmoidDesmoid-type fibromatosisFibromatosisSorafenibTKITyrosine kinase inhibitors

Substanzen

SorafenibAntineoplastic AgentsProtein Kinase InhibitorsNiacinamidePhenylurea Compounds

Autor:innen und Institutionen

  • Department of Medical Oncology, BRAIRCH, AIIMS, Delhi, India. Electronic address: vg18007@gmail.com.
  • Department of Medical Oncology, BRAIRCH, AIIMS, Delhi, India. Electronic address: bharathbg01@gmail.com.
  • Department of Medical Oncology, BRAIRCH, AIIMS, Delhi, India. Electronic address: samdoc_mamc@yahoo.com.
  • Department of Biostatistics, AIIMS, Delhi, India. Electronic address: aduaiims@gmail.com.
  • Department of Pathology, AIIMS, Delhi, India. Electronic address: adawad@gmail.com.
  • Department of Radiodiagnosis, BRAIRCH, AIIMS, Delhi, India. Electronic address: drektadhamija.aiims@gmail.com.

Zitieren

APA

Garg, V., Gangadharaiah, B. B., Rastogi, S., Upadhyay, A., Barwad, A., Dhamija, E., & Gamangatti, S. (2023). Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.03.017

Vancouver

Garg V, Gangadharaiah BB, Rastogi S, Upadhyay A, Barwad A, Dhamija E, et al. Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.03.017

BibTeX
@article{Garg2023,
  author = {Garg, Vikas and Gangadharaiah, Bharath B and Rastogi, Sameer and Upadhyay, Ashish and Barwad, Adarsh and Dhamija, Ekta and Gamangatti, Shivanand},
  title = {Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.03.017}
}
Kostenlos starten →